Intellia Therapeutics (NTLA) Retained Earnings (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Retained Earnings data on file, last reported at -$2.7 billion in Q1 2026.

• On a quarterly basis, Retained Earnings fell 254246.17% year-over-year to -$2.7 billion in Q1 2026; TTM through Mar 2026 was -$2.7 billion, a 254246.17% decrease from a year earlier, with the FY2025 full-year figure at -$2.6 billion, down 18.95% from the prior year.
• Retained Earnings for Q1 2026 stood at -$2.7 billion, down from -$2.6 billion in the prior quarter.
• Over the last five years, Retained Earnings for NTLA reached as high as $1.1 million in Q1 2025 and fell as low as -$2.7 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$1.1 billion across 5 years, with a median of -$1.1 billion in 2022.
• Across the five-year window, Retained Earnings plunged 7311830.77% in 2022 and soared 211.62% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$1.2 billion in 2022, then tumbled by 40.88% to -$1.7 billion in 2023, then tumbled by 31.3% to -$2.2 billion in 2024, then slipped by 18.95% to -$2.6 billion in 2025, then retreated by 3.72% to -$2.7 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$2.7 billion in Q1 2026, -$2.6 billion in Q4 2025, and -$2.5 billion in Q3 2025.